arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Coherus Oncology, Inc.

CHRS
$0.75 ▼ -0.11 (-12.29%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
55 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
39
Health
Weak
Neutral
auto_awesome

Analytical Summary

Coherus Oncology, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $116.1M
Dividend Yield —
Revenue Growth 39.5% ↘
Op. Margin -226.0% ↗
ROIC -42.0% ↘
FCF / Share $-0.40 ↗
Trailing P/E —
Price / Book 1.9x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

55-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$14.31M
↑ +39.5% —
Net Income Profit after all expenses
$-38.33M
↑ +32.2% —
Operating Margin Operating profit as % of sales
-226.0%
↑ +23.1% 0th
FCF / Share Free cash flow per share
$-0.40
↑ +5.5% —
Long-Term Debt Long-term obligations
$73.29M
— +0.2% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↓
0
Returns
100
Financial Health ↓
24
Cash Quality
11

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 15 years · 55 quarters